SPARSENTAN VS IRBESARTAN IN PATIENTS WITH IMMUNOGLOBULIN A NEPHROPATHY (IgAN): SUBGROUP ANALYSES OF 2-YEAR RESULTS FROM THE PIVOTAL PHASE 3 PROTECT TRIAL
Back
15 Apr 2024
15:35
15:45
Jonathan
Barratt
Free Communication
United Kingdom
University of Leicester, Leicester, UK
Add to My Schedule